ELDN
Eledon Pharmaceuticals, Inc.
$3.88
+0.52%
2026-05-08
About Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Key Fundamentals
Forward P/E
-4.81
EPS (TTM)
$-0.52
ROE
-35.8%
Profit Margin
0.0%
Debt/Equity
0.47
Price/Book
2.14
Beta
0.95
Market Cap
$298.5M
Avg Volume (10D)
1.3M
Recent Breakout Signals
No recent breakout signals detected for ELDN.
Recent Price Range (60 Days)
60D High
$4.20
60D Low
$1.98
Avg Volume
1.4M
Latest Close
$3.88
Get breakout alerts for ELDN
Sign up for Breakout Scanner to receive daily notifications when ELDN triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Eledon Pharmaceuticals, Inc. (ELDN) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ELDN daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ELDN operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.